Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.36 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.34 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.34 |
| ▸ | ACACB | O00763 | 5/20 | 0.32 |
| ▸ | TLR2 | O60603 | 2/20 | 0.32 |
| ▸ | KDM5A | P29375 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2337580 | 1.00 | ABL1 (0.39) | ABL1POLBDEGS1MTNR1AMTNR1B | |
| SCHEMBL2343120 | 0.84 | DEGS1 (0.37) | ABL1DEGS1MTNR1AMTNR1BACACB | |
| SCHEMBL3321139 | 0.84 | DEGS1 (0.37) | ABL1DEGS1MTNR1AMTNR1BACACB | |
| SCHEMBL2343085 | 0.84 | DEGS1 (0.37) | DEGS1MTNR1AMTNR1BACACB | |
| SCHEMBL2336745 | 0.80 | DEGS1 (0.50) | ABL1DEGS1ACACBCYP3A4 | |
| SCHEMBL2347988 | 0.80 | DEGS1 (0.50) | ABL1DEGS1ACACBCYP3A4 | |
| SCHEMBL2336740 | 0.80 | DEGS1 (0.50) | ABL1DEGS1ACACBCYP3A4 | |
| SCHEMBL2342388 | 0.79 | DEGS1 (0.34) | DEGS1MTNR1AMTNR1BACACB | |
| SCHEMBL3320103 | 0.79 | DEGS1 (0.34) | DEGS1MTNR1AMTNR1BACACB | |
| SCHEMBL2339441 | 0.77 | MAPT (0.44) | CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8642590-B2 | Alkylcyclohexylethers of dihydrotetraazabenzoazulenes | HOFFMANN-LA ROCHE INC. (US) | 2014-02-04 | — | — | US | disclosed |
| EP-2358714-B1 | ALKYLCYCLOHEXYLETHERS OF DIHYDROTETRAAZABENZOAZULENES | HOFFMANN LA ROCHE (CH) | 2012-08-01 | — | — | EP | disclosed |
| US-20100125066-A1 | ALKYLCYCLOHEXYLETHERS OF DIHYDROTETRAAZABENZOAZULENES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100125066-A1 | ALKYLCYCLOHEXYLETHERS OF DIHYDROTETRAAZABENZOAZULENES | AVPR1A, AVPR1B, OXTR | ABL1 1999/4885POLB 3231/4885DEGS1 784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.